Clinical trials: Dementia Severe
Moderate to Severe Dementia
Pilot Study of a Robot-assisted Intervention for the Management of Care-induced Pain in Dementia
Health care professionals lack tools to deal with acute pain in patients with moderate to severe dementia during daily nursing situations.
- Trial name
- PARODOL (NCT03591822)
- Testing
- A : Systemic evaluation of the pain and mediation with the PARO therapeutic robot, B : Systemic evaluation of the pain
- Where
- 5 sites in France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Major Depressive Disorder, Alzheimer Disease
Deep TMS for Comorbid Depression and Cognitive Impairment in Older Adults
In this study, the investigators will be examining the effects of the deep repetitive transcranial magnetic stimulation (rTMS) using the H1 coil in patients over the age of 60 diagnosed with mild to early-moderate Alzheimer's…
- Conditions
- Major Depressive Disorder, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- NCT03665831
- Testing
- Brainsway H1-Coil Deep TMS System
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- Rotman Research Institute at Baycrest
Alzheimer Disease
Bryostatin Treatment of Moderately Severe Alzheimer's Disease
To evaluate the safety, tolerability, and long-term efficacy of bryostatin 1 (hereafter referred to as bryostatin) for the treatment of moderately severe Alzheimer's disease (AD).
- Trial name
- NCT04538066
- Testing
- Bryostatin 1
- Where
- 19 sites in United States
- Volunteers
- 122 people
- Sponsor
- Neurotrope Bioscience, Inc.
Healthy Volunteers, Moderate to Severe Alzheimer Patients
A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease
This is a dual-centre, Phase I/IIa study, in healthy subjects and subjects with AD to investigate the safety, tolerability, cognitive, and behavioural effects of RPh201.
- Trial name
- NCT01513967
- Testing
- RPh201, botanical drug product
- Where
- 2 sites in Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Regenera Pharma Ltd
Major Depressive Disorder, Dementia
Vortioxetine in Patients With Depression and Early Dementia
This study evaluates the effectiveness of vortioxetine on depressive symptoms in patients with depression and early dementia
- Trial name
- MEMORY (NCT04294654)
- Testing
- Vortioxetine
- Where
- 24 sites in Estonia, France and 4 more
- Volunteers
- 82 people
- Sponsor
- H. Lundbeck A/S
Major Neurocognitive Disorder
TDCS as Augmentation Therapy to Cognitive Training in Mild Dementia
Due to increase in life expectancy, major neurocognitive disorder (MND) becoming increasingly important as reflected in the increasing number in dementia population, as well as in burden to health care system and to caregiver.
- Trial name
- NCT06559254
- Testing
- transcranial direct current stimulation
- Where
- Hong Kong
- Volunteers
- 36 people
- Sponsor
- Hospital Authority, Hong Kong
Dementia, Dementia Severe
Effects of FEED@Home Intervention
The main goal of this single-blinded multicenter randomized trial is to learn if the 8-week home-based Feeding EnhancEment in Dementia program (FEED@home) works to improve unplanned hospital utilization of advanced dementia…
- Trial name
- NCT06727461
- Testing
- Home-based Feeding EnhancEment in Dementia (Feed@home)
- Where
- Hong Kong
- Volunteers
- 180 people
- Sponsor
- The University of Hong Kong
Alzheimer Disease
Efficacy and Safety of Curcumin Formulation in Alzheimer's Disease
Curcumin is shown to impact several different pathways of neuroprotection, however clinical trials have not shown positive results, due to the poor bioavailability of curcumin.
- Trial name
- NCT01001637
- Testing
- Curcumin Formulation
- Where
- India
- Volunteers
- 26 people
- Sponsor
- Jaslok Hospital and Research Centre
Alzheimer Disease
Impact of Therapeutic Educational Programme on the Alzheimer's Disease Affected Patient's Quality of Life
Therapeutic education expands in Alzheimer's Disease management in France. Several studies revealed a positive impact on caregiver's burden and/or quality of life.
- Trial name
- THERAD (NCT01796314)
- Testing
- Therapeutic Educational Program
- Where
- France
- Volunteers
- 170 people
- Sponsor
- University Hospital, Toulouse
Alzheimer Disease, Dementia
CONSTELLATIONS Living Lab: Improving the Care Transitions of Older Adults Living with Neurocognitive Disorders
The prevalence of major neurocognitive disorders (MNCDs), particularly Alzheimer's disease, among older adults is increasing. These individuals and their caregivers often face challenges due to inefficient and poorly coordinated…
- Conditions
- Alzheimer Disease, Dementia, Neurocognitive Decline
- Trial name
- NCT06608589
- Testing
- CoMPAS+ MNCDs Program - Quality improvement program targeting the care transitions of patients living with a major neurocognitive disorder and their caregivers
- Where
- Canada
- Volunteers
- 700 people
- Sponsor
- Laval University
Moderate Dementia, Severe Dementia
Can Virtual Reality Reduce Depression and Agitation in Older Adults With Moderate to Severe Dementia?
Dementia is a term used to describe a collection of symptoms including memory loss, problems with reasoning and communication, and a reduction in a person's ability to carry out daily activities.
- Trial name
- NCT04347668
- Testing
- Virtual Reality, Usual Care
- Where
- 3 sites in Canada
- Volunteers
- 266 people
- Sponsor
- Western University, Canada
Parkinson's Disease Dementia
Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)
The purpose of this study is to provide long-term safety data for rivastigmine capsule and transdermal patch treatments, in particular the effect of rivastigmine on worsening of the underlying motor symptoms of Parkinson's…
- Trial name
- NCT00623103
- Testing
- Rivastigmine capsule, Rivastigmine transdermal patch
- Where
- 127 sites in United States, Argentina and 11 more
- Volunteers
- 583 people
- Sponsor
- Novartis
Severe Alzheimer Disease
A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease
This study will evaluate the safety, tolerability, and potential cognitive benefit of the experimental treatment GRF6019 in subjects with severe Alzheimer's disease.
- Trial name
- NCT03765762
- Testing
- GRF6019
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Alkahest, Inc.
Alzheimer's Disease, Dementia
Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease
This study will evaluate the pharmacological efficacy on language capability and compliance with combination of new Ebixa oral pump and donepezil compared to donepezil only in patients with probable Alzheimer's disease.
- Trial name
- ROMEO-AD (NCT01849042)
- Testing
- Ebixa, donepezil
- Where
- South Korea
- Volunteers
- 188 people
- Sponsor
- Konkuk University Medical Center
Neurocognitive Deficit
Concordance Between Mini-Mental Stats Examination (MMSE) and an Adapted Version of the MMSE in Reunion Island Population (MMS-Run)
Illeteracy concerns more than 38% of Réunion Island's people older than 65 years old, which makes it an important risk factor for dementia and a limit to neurocognitive test's administration.
- Trial name
- MMS-R-ep (NCT05858489)
- Testing
- Mini-Mental State Examination (MMSE)
- Where
- Reunion
- Volunteers
- 61 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Alzheimer's Disease, Huntington's Disease
A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function
This study is to compare the pharmacokinetics of Dimebon in subjects with severe renal impairment to subjects with normal renal function after oral administration of a single oral 20-mg dose of Dimebon.
- Trial name
- NCT00824590
- Testing
- Dimebon
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obstructive Sleep Apnea, Dementia
The Effect of OSA on Brain Waste Clearance
Recent ground-breaking research has shown that clearance of toxic neuro-metabolites from the brain including the proteins β-Amyloid (Aβ) and tau that form dementia causing plaques and tangles is markedly impaired when sleep is…
- Conditions
- Obstructive Sleep Apnea, Dementia, Cognitive Impairment
- Trial name
- NCT05606991
- Testing
- CPAP Withdrawal
- Where
- Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Woolcock Institute of Medical Research
Alzheimer Disease
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
This is a randomized double-blind Placebo-controlled, Phase 2 study comparing bryostatin to placebo for the treatment of moderately severe to severe Alzheimer's disease in subjects not receiving memantine treatment.
- Trial name
- NCT03560245
- Testing
- Bryostatin
- Where
- 28 sites in United States
- Volunteers
- 108 people
- Sponsor
- Neurotrope Bioscience, Inc.
Alzheimer's Disease
Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment
This is a prospective, multicenter, open-label study. Following screening and baseline assessments, eligible patients will be switched to rivastigmine and will enter the 16 week run-in rivastigmine treatment phase.
- Trial name
- NCT00234637
- Testing
- Rivastigmine, memantine
- Where
- France
- Volunteers
- 204 people
- Sponsor
- Novartis
Major Depressive Disorder
Pathophysiology of Neurodegeneration in Late-life Depression (AV45+THK)
Late-life depression has been frequently associated with cognitive impairment. Several meta-analyses consistently suggested that a history of depression approximately doubles an individual's risk for developing dementia later in…
- Trial name
- NCT03430869
- Testing
- F-18 AV-45, F-18-THK-5351
- Where
- Taiwan
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital